US-based healthcare technology developer Drawbridge Health was launched by conglomerate General Electric (GE) yesterday.
Drawbridge Health will develop technology geared towards integrating the abilty to draw, collect and stabilise samples in a single device that would eliminate the need for phlebotomy and patients travelling to blood draw centres.
The technology is also expected to enable blood being shipped at room temperature and streamlined downstream processing to ensure accurate, reliable results.
Lee McCracken has been appointed chief executive of the new startup, joining from molecular diagnostics company Gensignia Life Sciences where he had held the same position.
Risa Stack, general manager of new business creation at GE Ventures, the corporate venturing arm of GE, and Ger Brophy, general manager of cell therapy at General Electric company GE Healthcare Life Sciences, have joined the board of directors.
Stack said: “At GE we share technology, markets, structure and knowledge across our varied businesses, which uniquely positions us to tackle many issues, including this one.
“With Drawbridge Health, we are combining technology from GE Global Research, expertise from GE Healthcare and business models from GE Ventures to offer a simple, safe and more efficient solution that can help save time, money and lives.”